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High insulin levels are linked with increased cancer risk, including prostate cancer. We examined the associations between prostate
cancer with polymorphisms of the insulin gene (INS) and its neighbouring genes, tyrosine-hydroxylase and IGF-II (TH and IGF2). In this
study, 126 case–control pairs matched on age, race, and countries of origin were genotyped for +1127 INS-PstIi nINS, –4217 TH-PstI
in TH, and +3580 IGF2-MspIi nIGF2. The homozygous CC genotype of +1127 INS-PstI occurred in over 60% of the population. It
was associated with an increased risk of prostate cancer in nondiabetic Blacks and Caucasians (OR¼3.14, P¼0.008). The CC
genotype was also associated with a low Gleason score o7 (OR¼2.60, P¼0.022) and a late age of diagnosis (OR¼2.10,
P¼0.046). Markers in the neighbouring genes of INS showed only null to modest associations with prostate cancer. The
polymorphism of INS may play a role in the aetiology of prostate cancer. Given the high prevalence of the CC genotype and its
association with late age of onset of low-grade tumours, this polymorphism may contribute to the unique characteristics of prostate
cancer, namely a high prevalence of indolent cancers and the dramatic increase in incidence with age.
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The insulin-like growth factor (IGF) system, which includes two
ligands (IGF-I and IGF-II), two cell membrane receptors (IGF-1R
and IGF-2R), six binding proteins (IGFBP-1 through IGFBP-6),
and a large group of IGFBP proteases (Grimberg and Cohen, 2000;
Khandwala et al, 2000; Yu and Rohan, 2000), has been implicated
in carcinogenesis because of its important role in regulating
cell proliferation, differentiation, apoptosis, and transformation
(Grimberg and Cohen, 2000). There are several consistent
reports that link risk of prostate cancer with high serum levels
of IGF-I (Mantzoros et al, 1997; Chan et al, 1998; Wolk et al, 1998;
Stattin et al, 2000; Chokkalingam et al, 2001). Decreased levels of
IGFBP-3, the most abundant IGFBP in the circulation, have
been found in prostate cancer patients and in those with metastatic
diseases (Kanety et al, 1993; Chan et al, 1998; Chokkalingam
et al, 2001).
Insulin is hypothesised as a risk factor of prostate cancer
because of its structural and regulatory relations with the IGF
system. There is structural homology among insulin, IGF-I, and
IGF-II as well as between insulin receptor and IGF-1R (Khandwala
et al, 2000; Yu and Rohan, 2000), so insulin and IGFs can crossbind
to each other’s receptor although with weak affinity (Efstratiadis,
1998). Insulin regulates IGFBP-1 and may affect circulating levels
of free IGFs (Powell et al, 1991). In addition to its close relation
with the IGF system, the negative correlation between high insulin
and decreased sex hormone-binding protein (SHBP) may result in
increased levels of free testosterone (Strain et al, 1994; Pasquali
et al, 1995). So far, only one study in prostate cancer has examined
serum insulin levels using fasting blood. In this case–control study
conducted in China, men with insulin levels in the highest tertile
had a 2.5-fold increased risk of prostate cancer compared to men
in the lowest tertile after adjusting for IGF-I and anthropometric
factors (Hsing et al, 2001). One of the causes for elevated insulin
levels might be genetic variation in the insulin gene (INS). We
examined the relation between risk of prostate cancer and a single
nucleotide polymorphism (SNP) marker in INS in a case–control
study.
The insulin gene is located on chromosome 11 (11p15.5). The
variable number of tandem repeat (VNTR) that lies immediately
adjacent to the 50 promoter region of INS is believed to have a
direct effect on INS regulation (Kennedy et al, 1995). The
polymorphism of the VNTR can be classified into two main
groups: small class I alleles (28–44 repeats) and large class III
alleles (138–159 repeats) at frequencies of about 70 and 30%,
respectively, and class II alleles of intermediate size are rare (Stead
and Jeffreys, 2000). The class I allele is associated with increased
expression of insulin mRNA and insulin levels (Lucassen et al,
1995; Bennett and Todd, 1996; Le Stunff et al, 2000). The allelic
variation of VNTR is also associated with the risk of diabetes. It
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shas been found consistently that the class I allele increases the risk
of type I diabetes (Julier et al, 1991; Lucassen et al, 1993; Bennett
and Todd, 1996). An association between the class III allele and
type II diabetes has also been reported (Ong et al, 1999). In
addition to the VNTR, there are 10 noncoding SNP markers
that span the 4.1kb segment of the entire INS gene and its flanking
intergenic regions. It has been shown in Caucasian populat-
ions that these 10 SNPs are in tight linkage disequilibrium
with each other and with the VNTR such that they constitute
two major haplotypes (Cox et al, 1988; Julier et al, 1991; Lucassen
et al, 1993). In such a region of tight linkage disequilibrium,
assaying for one marker would generally provide genotype
information of all the others. We assayed for two of these
SNP markers, the +1127 INS-PstI and +1428 INS-FokI (the
positive number indicates the number of base pairs downstream
from the initiator codon of INS), as the surrogates for the
VNTR. We found complete concordance for genotypes at
these two markers in 50 subjects tested. Here, we reported
the results of the PstI marker in the entire study population.
The PstI marker was chosen for genotyping, since it was reported
to be in complete linkage disequilibrium with three other SNPs in
the INS genomic region, and genotypes for this marker were
almost always identical to those at the VNTR (Lucassen et al,
1993). To further show that INS, rather than adjacent genes on
chromosome 11, is indeed the risk-associated gene, we also
genotyped two markers in the tyrosine-hydroxylase and IGF-II
genes (TH and IGF2), which flank the 50 and 30 ends of INS,
respectively (Figure 1).
MATERIALS AND METHODS
In this case–control study, cases with histopathologically con-
firmed prostate cancer were identified from two hospitals affiliated
with the Albert Einstein College of Medicine. They were private
patients either diagnosed or treated at the Departments of Urology
in these hospitals. After obtaining a physician’s approval,
sequential patients who had no history of other cancers were
recruited within a year of diagnosis. For potential controls,
outpatients who were male and X40 years old were randomly
sampled from the billing records of the Departments of Medicine
in the same hospitals where the cases arose. Patients who had no
history of any cancer and had intact prostate and testes formed a
pool of eligible controls. The reasons for seeing an internist were
not used as exclusion criteria. One control was matched to each
case on birth year (75 years), race, and countries of origin.
Questionnaire data and nonfasting blood samples were obtained.
DNA was extracted from whole blood and genotyped for three
markers in the TH-INS-IGF2 region (Figure 1) by a polymerase
chain reaction-based restriction fragment length polymorphism
assay (PCR-RFLP). The study protocol was approved by the
institutional review board, and informed consent was obtained
from all subjects.
Between 1998 and 2000, 191 cases and 148 controls were
recruited. Genotyping was performed on 178 (93%) cases and 135
(91%) controls who had a DNA sample. Odds ratios for the
associations between polymorphisms and risk of prostate cancer
were estimated by conditional logistic regression in 126 case–
control pairs. A total of 52 cases were excluded from conditional
logistic regression analyses either because a control who fulfilled
the three matching factors was not available or the matched
control did not have genotype data. They were not different from
the 126 analysable cases in terms of age at diagnosis, Gleason
score, race, and genotype frequencies. Moreover, using all the
recruited cases and controls in unmatched analyses yielded similar
results. The results from conditional logistic regression were
presented, since it is the appropriate and standard statistical
method for analysing matched case–control data.
To examine the effects of the INS polymorphism on two
diagnostic characteristics, namely Gleason score (o7o rX7) and
age at diagnosis (o55, 55–64, or X65), case–case analyses were
performed among all the 178 cases. The cut point for Gleason score
was chosen for its association with tumour extent, prognosis, and
survival (Kattan et al, 1997; D’Amico et al, 1998). Treating Gleason
score and age at diagnosis as the outcome variables, logistic
regression analyses for dichotomous and ordinal dependent
variables, respectively, were performed to examine their associa-
tions with the INS polymorphism while controlling for confound-
ing variables. Data were analysed by the statistical software
package SAS (SAS Institute Inc., 1989). All P-values presented are
two-sided.
Three SNPs in three genes were genotyped in this study.
To measure the extent of linkage disequilibrium between any
pairwise markers, we first inferred phase and reconstructed
haplotypes using the PHASE software (http://www.stat.washington.
edu/stephens/phase.html) developed by Stephens et al (2001).
Linkage disequilibrium was measured by D0 (Devlin and
Risch, 1995).











































Figure 1 Position of SNPs examined in the TH-INS-IGF2 region on chromosome 11p15.5. This 19-kb genomic region, in which 19 polymorphisms have
been identified, includes the tyrosine hydroxylase (TH), insulin (INS), and IGF-II (IGF2) genes (Lucassen et al, 1993). Three SNPs were examined in this study
and are designated by their position (the positive and negative numbers indicate the number of base pairs downstream and upstream from the initiator
codon of INS, respectively), corresponding gene, and the restriction enzyme used for detection: (a) –4217 T/C polymorphism of TH detected by PstI,
(b) +1127 T/C polymorphism of INS detected by PstI, and (c) +3580 G/A polymorphism of IGF2 detected by MspI. Open, closed, and hatched boxes refer
to introns, exons, and untranslated regions, respectively. The triangle represents the variable number of tandem repeat (VNTR) locus adjacent to the
promoter region of INS. Figure not drawn to scale.
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sPCR-RFLP assays for detection of polymorphisms
Primers to amplify the three genomic regions are:
INS+1035 GGG TCC CCT GCA GAA GCG TGG CA
INS+1597 CTC CCT CCA CAG GGA CTC CAT C
TH-PstF TGA CGC CAA GGA CAA GCT CAG GT
TH-PstR CCA CCC AGC AGC CCC AGT CCT GT
IGF2-MspF CCA CCC CTT CTG GGA AGC TAA AAG
IGF2-MspR CCC TCG GTC CTC CAG GAA TGG ACA
The TH and IGF2 amplicons were amplified using standard Taq
DNA polymerase with cycling plateaus of 941–551–721 for
30seconds each (35 cycles). The INS amplicon was more refractory
to reliable amplification with Taq DNA polymerase. We used LA
Taq, a DNA polymerase mix, with a proofreading enzyme in order
to obtain reliable amplification. Amplified DNA (5ml) was used in
a1 0ml restriction enzyme digest with 1–2U of enzyme using the
manufacturer’s recommendations. Digested products were size
fractionated on high percentage agarose gels and visualised by UV-
induced ethidium fluorescence. The restriction fragments of the
alleles are as follows:
INS T allele 562bp
C allele 470bp+92bp
TH T allele 240bp
C allele 148bp+92bp
IGF2 A allele 122bp+118bp
G allele 122bp+84bp+34bp
RESULTS
The age at diagnosis of the prostate cancer cases ranged from 43 to
88 years, with a median at 63. The majority of the cases (77%) were
diagnosed due to an abnormal PSA test or digital rectal
examination. The ethnic distribution of the cases was 54% African
Americans, 22% Caucasians, 21% Hispanics, and 3% others,
reflecting the ethnic distribution of the population in the
catchment area. Genotype frequencies of the three markers in
the TH-INS-IGF2 region by ethnicity are presented in Table 1. The
+1127 INS-PstI marker was in linkage disequilibrium with both –
4217 TH-PstI and +3580 IGF2-MspI in the neighbouring genes
(Table 1). The C alleles of –4217 TH-PstI were linked to the C
alleles of +1127 INS-PstI, resulting in a linkage disequilibrium
score (D0) of one; the two markers, however, were not in complete
linkage disequilibrium. For +1127 INS-PstI, the homozygous CC
was the predominant genotype. The heterozygous CT and
homozygous TT were grouped together as the ‘other genotypes’
in analyses due to small numbers.
Table 2 shows that individuals with homozygous CC for +1127
INS-PstI had almost a two-fold increased risk of prostate cancer as
compared to those with other genotypes (OR¼1.74). As the
polymorphism at +1127 INS-PstI and its tightly linked VNTR have
been reported to be associated with diabetes (Lucassen et al, 1993),
we first stratified the analysis by diabetes status, which was based
on self-report. There was a disparity by diabetes status, such that
the association between +1127 INS-PstI and prostate cancer was
apparent among subjects without diabetes (OR¼2.18) but not
among those with diabetes (OR¼1.13). Subsequent analyses were
then limited to case–control pairs in which both members were
nondiabetic. We then evaluated if there was heterogeneity in
disease association by ethnicity. Stratified analyses by ethnicity
showed that association existed among the nondiabetic Black
subjects (OR¼2.75) and Caucasians (OR¼3.67), but not the
Hispanics (OR¼0.25). The sample size for the Hispanics was
small, and their genotype frequencies of +1127 INS-PstI were also
not in Hardy–Weinberg equilibrium. The genetic effect was age-
dependent: the strongest association between the CC genotype and
increased risk of prostate cancer occurred among subjects who
were Black or Caucasian and X55 years old (ORs for o55, 55–64,
and X65¼0.75, 5.0, and 9.0, respectively).
Table 1 showed that linkage disequilibrium existed between
+1127 INS-PstI and the two markers in the flanking neighbouring
genes. It is possible that a locus adjacent to INS is in fact the
disease-associated gene, and the observed association with +1127
INS-PstI is due to linkage disequilibrium between polymorphisms
of the disease-associated gene and INS. If so, polymorphism of the
Table 1 Percent distributions of the genotypes and pairwise linkage disequilibrium scores for three markers in the TH-INS-IGF2 region stratified by
ethnicity
All races
a Black Caucasian Hispanic
Cases Controls Cases Controls Cases Controls Cases Controls
N=178 (%) N=135 (%) N=96 (%) N=67 (%) N=40 (%) N=36 (%) N=37 (%) N=29 (%)
+1127 INS-PstI
CC 80 70 81 72 80 61 73 79
CT 18 26 18 27 17 33 24 10
T T 2 4 11363 1 0
–4217 TH-PstI
CC 13 17 8 5 25 33 14 25
CT 43 31 39 20 47 42 43 36
TT 44 52 53 75 28 25 43 39
+3580 IGF2-MspI
GG 42 42 50 37 25 49 41 50
AG 40 46 37 53 55 41 32 37
AA 18 11 13 10 20 10 27 13
Linkage disequilibrium score (D0)
b
+1127 INS-PstI and –4217 TH-PstI 0.76 1 1
+1127 INS-PstI and +3580 IGF2-MspI 0.85 0.80 0.87
–4217 TH-PstI and +3580 IGF2-MspI 0.49 0.45 0.31
aSubjects with mixed ethnicity were included here, but not in the race-specific columns.
bD0 was determined with cases and controls combined.
Insulin polymorphism and prostate cancer
GYF Ho et al
265



















sdisease-associated gene should demonstrate a stronger association
with prostate cancer than +1127 INS-PstI. Table 3 shows that
prostate cancer remained to have the strongest association with the
CC genotype of +1127 INS-PstI (OR¼3.57); the associations with
–4217 TH-PstI (CT vs TT, OR¼2.27) and +3580 IGF2-MspI (AA vs
GG, OR¼1.52) were comparatively moderate. Moreover, the
association between –4217 TH-PstI and prostate cancer was
attributed to the heterozygous genotype, the OR did not increase
for the homozygous, and hence the association lacked a gene-
dosage trend.
In Table 4, the case–case analyses showed that prostate cancer
patients with the CC genotype, as compared to those with other
genotypes, were more likely to have a low Gleason score o 7
(OR¼2.60) after controlling for variables that were significantly
associated with Gleason score, namely age at diagnosis and
frequency of seeing a physician for physical examination. The CC
genotype was also associated with a late age of diagnosis
(OR¼2.10) after adjusting for Gleason score and frequency of
physical examination.
DISCUSSION
The role of insulin in the aetiology of prostate cancer is implicated
by the observations from this and another study in China that
increased risk of prostate cancer was associated with genetic
Table 2 Odds ratios for the association between prostate cancer and the homozygous CC genotype of
+1127 INS-PstI
No of pairs OR (95% CI)
a P-value
All subjects 126 1.74 (0.99–3.05) 0.055
By diabetes status
No 86 2.18 (1.07–4.45) 0.032
Yes
b 40 1.13 (0.43–2.92) 0.809
By race, among nondiabetics
Black 45 2.75 (0.88–8.64) 0.083
Caucasian 26 3.67 (1.02–13.14) 0.046
Hispanic 14 0.25 (0.03–2.24) 0.215
Black and Caucasian, among nondiabetics 71 3.14 (1.34–7.36) 0.008
By age, among nondiabetic Black and Caucasian
c
o55 14 0.75 (0.17–3.35) 0.706
X55 57 6.33 (1.87–21.4) 0.003
aOdds ratios for the risk of prostate cancer when subjects with homozygous CC were compared with those with other
genotypes (the heterozygous and homozygous TT), with the latter as the reference group.
bOne or both members of the
pair had diabetes.
cThe case’s age at diagnosis was used for classification of the pair. P-value for homogeneity of odds ratios
(i.e. interaction between age and the +1127 INS-PstI polymorphism)=0.030.
Table 3 Associations between prostate cancer and three markers in the







CT or TT 1
CC 3.57 (1.35–9.45) 0.010
–4217 TH-PstI
TT 1
CT 2.27 (0.99–5.19) 0.053




AG 0.90 (0.42–1.95) 0.797
AA 1.52 (0.37–6.27) 0.559
aOdds ratios were adjusted for the other two markers in the model.
bIGF2 is subject
to parental imprinting, and only the paternal allele is expressed. OR for the
heterozygous genotype was difficult to interpret, when the expressing allele (A or G)
was not identified. Conversely, knowing the active allele among the subjects with
homozygous AA or GG was irrelevant. Hence, the OR for the homozygous AA was
fully interpretable when the homozygous GG was used as the reference.














2–6 116 84 0.034 2.60 (1.15–5.88)
a 0.022




X65 80 84 0.121
b 2.10 (1.01–4.33)
c 0.046
aOdds ratios for the risk of having a low Gleason score o7 were obtained from logistic regression analysis, when the subjects with homozygous CC were compared with those
with other genotypes (reference category). Odds ratio was adjusted for age at diagnosis (o55, 55–64, or X65) and frequency of seeing a doctor for physical examination (less
than once a year, once a year, or more than once a year).
bP for trend.
cOdds ratios were estimated from ordinal logistic regression analysis. The positive odds ratio (2.10)
indicates that the subjects with homozygous CC were more likely to be in a higher category of age at diagnosis (i.e. diagnosed at a later age) than subjects with other genotypes.
The odds ratio was adjusted for Gleason score (2–6 or X7) and frequency of seeing a doctor for physical examination.
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svariation in INS, but not its neighbouring genes, as well as elevated
fasting insulin levels (Hsing et al, 2001). Epidemiological studies
have also found a positive correlation between insulin levels and
risk of various cancers, such as colon, breast, and endometrial
cancers (Maggino et al, 1993; Gamayunova et al, 1997; Troisi et al,
1997; Del Giudice et al, 1998; Schoen et al, 1999; Josefson, 2000;
Kaaks et al, 2000; Yang et al, 2001; Goodwin et al, 2002). Biological
mechanisms that support the tumorigenic effects of insulin include
the following: (a) Insulin regulates and stimulates cell growth
through binding to its receptor (Van Obberghen and Gammeltoft,
1986; Denton and Tavare, 1995; Moule and Denton, 1997).
However, mitogenicity appears to occur at supraphysiologic levels
of insulin. (b) It inhibits apoptosis in different cellular models
(Park et al, 2000; Qian et al, 2001). (c) Insulin, IGF-I and IGF-II
share about 50% structural homology, and there is 60% homology
between insulin receptor and IGF-1R. Insulin and IGFs can
crossbind to each other’s receptor or to hybrid insulin and IGF-I
receptors, although the affinity is weak (Soos et al, 1990;
Efstratiadis, 1998). In some in vitro studies, the growth-promoting
effects of insulin are mediated primarily by its low-affinity
interaction with IGF-1R (Straus, 1984). (d) Insulin is the primary
regulator of IGFBP-1. It inhibits transcription of IGFBP-1, and this
may increase unbound, circulating IGFs (Powell et al, 1991). (e)
Insulin decreases the synthesis of (SHBP) and may thereby
increase the bioavailability of free steroids (e.g. testosterone) for
hormone-dependent tissues like the prostate (Strain et al, 1994;
Pasquali et al, 1995).
The +1127 INS-PstI marker is located in the 30 untranslated
region (UTR) of INS, and the UTR regions of the preproinsulin
mRNA have recently been demonstrated to play crucial roles in
regulating insulin production. The 30-UTR of INS suppresses
translation and also stabilizes the mRNA. It acts cooperatively with
the 50-UTR and markedly increases glucose-induced proinsulin
biosynthesis (Wicksteed et al, 2001). Therefore, the polymorphism
at +1127 INS-PstI, although located in an untranslated region, may
have a functional effect on the expression of INS.
The +1127 INS-PstI polymorphism may also be in intragenic
linkage disequilibrium with a causal mutation in INS. In Caucasian
populations in the US and Europe, the +1127 INS-PstI polymorph-
ism and nine other noncoding markers within the INS region are in
tight linkage disequilibrium with the VNTR locus, which is located
only 365bp from the start of transcription for insulin (Cox et al,
1988; Julier et al, 1991; Lucassen et al, 1993). The class I allele of
the VNTR is related to overexpression of insulin mRNA and
increased insulin levels in some studies (Lucassen et al, 1995;
Bennett and Todd, 1996; Le Stunff et al, 2000). The C allele of
+1127 INS-PstI, which was associated with increased risk of
prostate cancer in this study, is linked with the class I allele of the
VNTR. The extent of linkage disequilibrium across the insulin
gene and VNTR, however, has never been studied in the Blacks or
Hispanics. Hence it is not known if +1127 INS-PstI is also a
surrogate for the VNTR in the non-Whites in this study.
Nevertheless, the significant linkage disequilibrium in the Cauca-
sians suggests a strong evolutionary selection (Lucassen et al,
1993), and it is likely that strong linkage disequilibrium also exists
in other populations as has been shown in a Chinese population
(Cox et al, 1988).
Finally, there remains the possibility that INS is not the risk-
associated gene, and that +1127 INS-PstI is in linkage disequili-
brium with another marker in a disease-causing gene. It is
unlikely, since INS showed the strongest association with risk of
prostate cancer, as the strength of association dropped off with the
two neighbouring genes. It is, however, not surprising to see
residual association between prostate cancer and the CT genotype
of –4217 TH-PstI (OR¼2.27), since the +1127 INS-PstI and –4217
TH-PstI markers were in linkage disequilibrium.
If the polymorphism at +1127 INS-PstI increases prostate cancer
risk via altered insulin levels, this may explain its lack of
association with prostate cancer among the diabetics. The insulin
levels of the diabetics can be manipulated by medical intervention,
rendering the genotype irrelevant for cancer risk. Other treatment
for diabetes, such as weight reduction, could potentially modify the
genetic susceptibility to prostate cancer. Since the +1127 INS-PstI
marker and its tightly linked VNTR are associated with the risk of
diabetes and different alleles are involved in type I vs. type II
diabetes (Julier et al, 1991; Lucassen et al, 1993; Bennett and Todd,
1996; Ong et al, 1999; Le Stunff et al, 2000), the allele frequencies of
+1127 INS-PstI could potentially be affected by the cause and type
of diabetes in both the diabetic cases and controls. The association
between prostate cancer and the +1127 INS-PstI marker could be
muddled in the diabetics – a heterogeneous group with diverse
aetiology, type, and treatment of diabetes as well as endogenous
and exogenous insulin. The nondiabetics were simply a group
without the complications from a complex disease.
Unlike the Black and Caucasian years, a negative association
between the CC genotype and prostate cancer was observed among
the Hispanics. This could be because of small sample size or a
population stratification bias. We examined for Hardy–Weinberg
equilibrium of the genotype frequencies of +1127 INS-PstI by the
likelihood ratio test among the controls (Lange, 1997). Hardy–
Weinberg equilibrium was found in both the Caucasians and
Blacks, but not in the Hispanic population, in which the frequency
of the homozygous TT was higher than expected (Po0.0001).
Population admixture, one of the factors that could alter allele
frequencies in the Hispanics, may cause biased results in
association studies (Ewens and Spielman, 1995).
It is interesting that although the polymorphism at +1127 INS-
PstI increased the risk for prostate cancer, it was associated with
favourable clinical characteristics of the tumour. After adjusting
for frequency of physical examination by a clinician, a proxy for
access to health care, the CC genotype was associated with late age
at diagnosis and low Gleason score. The results suggest that genetic
effects take time to accumulate and manifest while affecting the
prostate tissue slowly. Alternatively, the age-dependent penetrance
of INS may be elevated through interaction with some unknown
ageing factors.
Our data suggest that the insulin gene plays a role in the
aetiology of prostate cancer. Given the high prevalence of the
homozygous CC genotype (460% in this study population), its
population attributable risk can be high. Moreover, given its
association with late age of onset of low-grade prostate tumors, the
polymorphism at +1127 INS-PstI may contribute to the unique
features of prostate cancer that are not seen in other cancers,
namely the high prevalence of latent and indolent cancers and the
dramatic increase in incidence with age.
Finally, although the polymorphisms of INS have been studied
for their roles in diabetes and obesity (Julier et al, 1991; Lucassen
et al, 1993; Bennett and Todd, 1996; Ong et al, 1999), this is the
first published report on the association between the INS gene and
risk of cancer. As a result of our small sample size, our results need
to be replicated by population-based studies with a sample size
sufficient to confirm various subgroup associations. Another
limitation of this study is that fasting blood samples and hence
insulin levels were not available. We were not able to examine the
hypothesis that the disease association of the polymorphism at
+1127 INS-PstI is mediated through altered insulin levels. The
available data in the literature have shown that (a) high insulin or
C-peptide levels (an indicator for the pancreatic secretion of
insulin) are associated with increased risk of cancer (e.g. prostate,
colon, breast, and endometrial cancer) (Maggino et al, 1993;
Gamayunova et al, 1997; Troisi et al, 1997; Del Giudice et al, 1998;
Schoen et al, 1999; Josefson, 2000; Kaaks et al, 2000; Hsing et al,
2001; Yang et al, 2001; Goodwin et al, 2002), (b) there is a
relationship between the VNTR allelic variation and INS expres-
sion and/or production (Lucassen et al, 1995; Bennett and Todd,
1996; Le Stunff et al, 2000), and (c) there appears to be an
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sassociation between a SNP tightly linked with the VNTR and the
risk of prostate cancer. Future studies on cancer should examine
comprehensively the inter-relationships among fasting insulin
levels, insulin sensitivity, polymorphisms of the INS gene (either
the VNTR or one of the surrogate SNPs), and risk of cancer.
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